PXMD (PaxMedica) NonCurrent Deferred Liabilities: $0.50 Mil (As of Sep. 2024)


What is PaxMedica NonCurrent Deferred Liabilities?

PaxMedica PXMD +40.00% NonCurrent Deferred Liabilities is $0.50 Mil as of Sep. 2024.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

PaxMedica's non-current deferred liabilities for the quarter that ended in Sep. 2024 was $0.50 Mil.

PaxMedica NonCurrent Deferred Liabilities Related Terms

PaxMedica NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for PaxMedica's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica NonCurrent Deferred Liabilities Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.50

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.50 0.50 0.50 0.50
What does a NonCurrent Deferred Liabilities of $0.50 Mil mean?
PaxMedica (PXMD) has a NonCurrent Deferred Liabilities of $0.50 Mil as of Sep. 2024. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on PaxMedica and its competitors.
Is PaxMedica's NonCurrent Deferred Liabilities too high?
PaxMedica's current NonCurrent Deferred Liabilities is $0.50 Mil.
How does PaxMedica's NonCurrent Deferred Liabilities compare to BTAX and NBIO?
PaxMedica's NonCurrent Deferred Liabilities of $0.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on PaxMedica and its competitors. PaxMedica's current NonCurrent Deferred Liabilities is $0.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (PXMD) has a current NonCurrent Deferred Liabilities of $0.50 Mil. The current NonCurrent Deferred Liabilities is $0.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For PaxMedica (PXMD), the current NonCurrent Deferred Liabilities is $0.50 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.